Aligos Therapeutics announced an ePoster flash session presentation at the 34th European Society of Clinical Microbiology and Infectious Diseases, or ESCMID, 2024, being held April 27-30 in Barcelona, Spain. The presentation highlights ALG-097558 Phase 1 data showing that single and multiple doses of this potent, pan-coronavirus protease inhibitor were well tolerated in healthy volunteers with a PK profile supporting twice daily ritonavir-free dosing without a food effect.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALGS:
- Aligos Therapeutics Presents Positive Clinical Data at ESCMID 2024 from the ALG-097558 Phase 1 Study
- Aligos dosing initiated in Phase 2a HERALD study of ALG-055009, data due in Q4
- Aligos presents data at APASL 2024 from ALG-055009, ALG-000184 studies
- Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 Studies
- Aligos Therapeutics initiates Phase 2a HERALD study of ALG-055009